CEL-SCI Corp. has received the second interim review of the safety data from its open-label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection). The review, conducted by an Independent Data Monitoring Committee (IDMC), reported that the data raised no safety concerns, and recommended that the Phase III study continue unmodified. CEL-SCI management considers the results of the review to be important since studies have shown that as much as 30% of Phas...